Tata India Pharma & Healthcare Fund - Dividend - Direct Plan

  • Previous Nav

  • Net Change on 29-09-2020

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Dividend | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

Investment objective of the scheme is to provide long term capital appreciation by investing predominantly in equity/equity related instruments of the companies in the Pharma&Healthcare sectors in India. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The Scheme does not assure or guarantee any returns.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
NIFTY PHARMA - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund - Direct Plan Dividend Plan Jan 01, 2013 58.21 20.74 8.71 1.31 3,652.59
SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -DIVIDEND Jan 01, 2013 62.42 14.57 4.78 1.15 1,360.70
UTI Healthcare Fund -Direct Plan - Income Option Jan 01, 2013 64.18 17.20 6.47 1.85 563.44

Fund Holdings as on 31-August-2020

  • DR REDDYs LABORATORIES LTD

  • SUN PHARMACEUTICAL INDUSTRIES LTD

  • DIVI LABORATORIES LTD

  • CIPLA LTD

  • IPCA LABORATORIES LTD

  • LUPIN LTD

  • A) REPO

  • AUROBINDO PHARMA LTD

  • NARAYANA HRUDAYALAYA LTD

  • PROCTER & GAMBLE HEALTH LTD

  • NATCO PHARMA LTD

  • LAURUS LABS LTD

  • SYNGENE INTERNATIONAL LTD

  • ALKEM LABORATORIES LTD

  • APOLLO HOSPITALS ENTERPRISE LTD

  • HEALTHCARE GLOBAL ENTERPRISES LTD

  • ABBOTT INDIA LTD

  • INDOCO REMEDIES LTD

  • CADILA HEALTHCARE LTD

  • DR. LAL PATH LABS LTD

  • ASTRAZENECA PHARMA INDIA LTD

  • NET CURRENT LIABILITIES

View More
  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

View More

About Tata India Pharma & Healthcare Fund

Scheme Analysis

Tata India Pharma & Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Tata Mutual Fund. It was launched on 28-Dec-2015 and currently has an AUM of ₹295.90 crore. Tata India Pharma & Healthcare Fund is benchmarked against NIFTY 50 - TRI as primary index and NIFTY PHARMA - TRI as secondary index.

The NAV of Tata India Pharma & Healthcare Fund ended down ₹-0.04(-0.31%)yesterday to ₹14.6244.

Among its top 3 holdings the fund has exposure to DR REDDYs LABORATORIES LTD, and

The Tata India Pharma & Healthcare Fund is managed by Rahul Singh and Meeta Shetty.

Fund House Contact

1903, B Wing, Parinee Crescenzo, G Block, Bandra Kurla Complex, Bandra East, Mumbai - 400 051

+91 (22) 66578282
kiran@tataamc.com
+91 (22) 22613782